DeepMed Research

EISAI INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Phase 1

Terminated

Conditions: Advanced or Metastatic Solid Tumors
Previously Untreated Gastric Cancer

Interventions: Drug: E7050
Drug: cisplatin
Drug: capecitabine

First Posted Date: 2011-05-18

Last Posted Date: 2017-05-15

Lead Sponsor: Eisai Inc.

Target Recruit Count: 7

Registration Number: NCT01355302

Locations: 🇺🇸
Boca Raton Clinical Research Associates, Inc, Plantation, Florida, United States
🇺🇸
Robert H. Lurie Comprenhensive Cancer Center of Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 16 locations

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Phase 2

Completed

Conditions: Thrombocytopenia

Interventions: Drug: Placebo
Drug: Avatrombopag
Drug: Pegylated interferon (PEG-IFN)
Drug: Telaprevir
Drug: Ribavirin

First Posted Date: 2011-05-18

Last Posted Date: 2018-02-22

Lead Sponsor: Eisai Inc.

Target Recruit Count: 65

Registration Number: NCT01355289

Locations: 🇺🇸
Health Care Consultants, Los Angeles, California, United States
🇺🇸
Metropolitan Research, Fairfax, Virginia, United States

A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma

Phase 3

Withdrawn

Conditions: Peripheral T-Cell Lymphoma

Interventions: Drug: E7777

First Posted Date: 2011-05-18

Last Posted Date: 2013-11-18

Lead Sponsor: Eisai Inc.

Registration Number: NCT01355783

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Phase 1

Terminated

Conditions: Rectal Cancer
Colon Cancer

Interventions: Drug: E7820
Drug: FOLFIRI

First Posted Date: 2011-05-04

Last Posted Date: 2023-06-22

Lead Sponsor: Eisai Inc.

Target Recruit Count: 82

Registration Number: NCT01347645

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma

Interventions: Biological: MORAb-004 (monoclonal antibody)

First Posted Date: 2011-04-13

Last Posted Date: 2021-09-01

Lead Sponsor: Eisai Inc.

Target Recruit Count: 76

Registration Number: NCT01335009

Locations: 🇺🇸
University of Iowa Hospital, Iowa City, Iowa, United States
🇺🇸
Atlantic Health, Morristown, New Jersey, United States
🇺🇸
New York University Cancer Institute, New York, New York, United States

and more 26 locations

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Phase 1

Completed

Conditions: Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: E7050
Drug: Cetuximab

First Posted Date: 2011-04-11

Last Posted Date: 2022-01-03

Lead Sponsor: Eisai Inc.

Target Recruit Count: 95

Registration Number: NCT01332266

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Phase 3

Completed

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
Drug: Eribulin mesylate 1.4 mg/m^2 intravenous

First Posted Date: 2011-04-04

Last Posted Date: 2023-06-22

Lead Sponsor: Eisai Inc.

Target Recruit Count: 452

Registration Number: NCT01327885

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Phase 1

Completed

Conditions: Purpura, Thrombocytopenic, Idiopathic
Acute Idiopathic Thrombocytopenic Purpura
Chronic Thrombocytopenia

Interventions: Drug: E5501 40 mg 2 x 20-mg tablets, orally, fasted
Drug: E5501 40 mg 2 x 20-mg tablets, orally, with food
Drug: E5501 40mg 2 x 20-mg tablets, orally, fasted

First Posted Date: 2011-04-04

Last Posted Date: 2012-03-09

Lead Sponsor: Eisai Inc.

Target Recruit Count: 84

Registration Number: NCT01327872

Locations: 🇳🇱
PRA Early Development Services, Zuidlaren, Netherlands

Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia

Phase 3

Completed

Conditions: Parkinson's Disease
Dementia

Interventions: Drug: Prior Donepezil 5mg
Drug: Prior Donzepezil 10mg
Drug: Prior Placebo

First Posted Date: 2011-04-04

Last Posted Date: 2015-11-03

Lead Sponsor: Eisai Inc.

Target Recruit Count: 357

Registration Number: NCT01327859

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

Phase 2

Completed

Conditions: HER2-normal

Interventions: Drug: eribulin mesylate

First Posted Date: 2011-04-04

Last Posted Date: 2019-08-20

Lead Sponsor: Eisai Inc.

Target Recruit Count: 81

Registration Number: NCT01328249

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center ,Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy